文献速递泌尿男性生殖肿瘤

HSD3B1基因型与放疗后生化复发前列腺癌ADT疗效的关联

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该回顾性研究纳入1996-2013年在Dana-Farber癌症研究所因放疗后生化复发接受ADT治疗的213例前列腺癌患者,检测HSD3B1(1245C)基因型。

要点

  • HSD3B1(1245C)变异等位基因数与放疗后ADT治疗的转移风险相关。
  • 多因素分析中2个变异等位基因者转移调整HR为2.01(95%CI 1.02-3.97)。

核心结论

  • 在因前列腺癌原发放疗后生化复发接受ADT治疗的男性中,HSD3B1(1245C)等位基因与更快的转移发生相关。

研究设计与样本

  • 利用Dana-Farber癌症研究所前列腺临床研究信息系统识别1996-2013年间因原发放疗后生化复发接受ADT治疗的男性队列,回顾性确定HSD3B1基因型;共识别218例合格男性,213例(98%)成功基因分型。

主要发现

  • 213例中携带0、1、2个变异等位基因者分别为97例(46%)、96例(45%)、20例(9%);总体变异等位基因频率为136/426(32%)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The variant HSD3B1 (1245C) allele enhances dihydrotestosterone synthesis and predicts resistance to androgen-deprivation therapy (ADT) for biochemically recurrent prostate cancer after prostatectomy and for metastatic disease. Whether this is true after radiotherapy is unknown. OBJECTIVE: To determine whether the HSD3B1 (1245C) allele predicts worse clinical outcomes from ADT for biochemical recurrence after radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: The Prostate Clinical Research Information System at Dana-Farber Cancer Institute was used to identify the study cohort, which included men treated with ADT for biochemical recurrence after primary radiotherapy between 1996 and 2013. We retrospectively determined HSD3B1 genotype. MAIN OUTCOMES AND MEASURES: Time to progression, time to metastasis, and overall survival according to genotype. Demographic and treatment characteristics were evaluated for confounders. Multivariable analyses were performed to adjust for known prognostic factors. RESULTS: A total of 218 eligible men were identified, of whom 213 (98%) were successfully genotyped. Of these, 97 of 213 (46%), 96 of 213 (45%) and 20 of 213 (9%) carried 0, 1, and 2 variant alleles. Overall variant allele frequency was 136 of 426 alleles (32%). Median patient age (interquartile range) was 69 (63-74), 72 (65-78), and 69 (65-77) years for 0, 1, and 2 variant alleles (P = .03). Demographic and treatment factors were otherwise similar. During a median follow-up of 7.9 years, median time to progression was 2.3 years (95% CI, 1.6-3.1 years) with 0 variant alleles, 2.3 years (95% CI, 1.5-3.3 years) with 1 variant allele, and 1.4 years (95% CI, 0.7-3.3 years) with 2 variant alleles (P = .68). Median time to metastasis diminished with the number of variant alleles inherited: 7.4 (95% CI, 6.7-9.7), 5.8 (95% CI, 4.9-6.5), and 4.4 (95% CI, 3.0-5.7) years, with inheritance of 0, 1, and 2 variant alleles, respectively (P = .03). Median OS was 7.7 (95% CI, 6.7-10.3), 6.9 (95% CI, 5.8-8.4), and 7.2 (95% CI, 3.8-7.9) years with inheritance of 0, 1, and 2 variant alleles, respectively (P = .31). On multivariable analysis with 0 variant alleles as the reference, the adjusted hazard ratio for metastasis was 1.19 (95% CI, 0.74-1.92) (P = .48) for 1 variant allele and 2.01 (95% CI, 1.02-3.97) (P = .045) for 2 variant alleles. Multivariable analysis did not demonstrate significant differences in TTP or OS. CONCLUSIONS AND RELEVANCE: In this study, the HSD3B1 (1245C) allele was associated with more rapid development of metastases in men treated with ADT for biochemical recurrence after primary radiation therapy for prostate cancer. Notably, 105 of 213 men (49%) had received prior ADT, and 119 of 213 (56%) received an androgen receptor antagonist during salvage treatment, both of which may attenuate the effect of the variant allele.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hearn JWD, Xie W, Nakabayashi M, et al. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA Oncol. 2018. PMID: 29049492. doi:10.1001/jamaoncol.2017.3164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。